KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Operations (2016 - 2025)

Vertex Pharmaceuticals has reported Cash from Operations over the past 17 years, most recently at 498000000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 498000000.0 for Q4 2025, down 14.81% from a year ago — trailing twelve months through Dec 2025 was 3631400000.0 (up 837.19% YoY), and the annual figure for FY2025 was 3631400000.0, up 837.19%.
  • Cash from Operations for Q4 2025 was 498000000.0 at Vertex Pharmaceuticals, down from 1241400000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for VRTX hit a ceiling of 1369800000.0 in Q3 2024 and a floor of 3753600000.0 in Q2 2024.
  • Median Cash from Operations over the past 5 years was 955850000.0 (2022), compared with a mean of 672475000.0.
  • Biggest five-year swings in Cash from Operations: surged 670.76% in 2022 and later plummeted 430.89% in 2024.
  • Vertex Pharmaceuticals' Cash from Operations stood at 995000000.0 in 2021, then increased by 8.38% to 1078400000.0 in 2022, then plummeted by 78.25% to 234600000.0 in 2023, then surged by 149.19% to 584600000.0 in 2024, then fell by 14.81% to 498000000.0 in 2025.
  • The last three reported values for Cash from Operations were 498000000.0 (Q4 2025), 1241400000.0 (Q3 2025), and 1073100000.0 (Q2 2025) per Business Quant data.